A Study of Fixed-Dose Rate Gemcitabine, Cisplatin, and Bevacizumab in Previously Untreated Patients With Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2012
At a glance
- Drugs Bevacizumab; Cisplatin; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Apr 2008 Results published in Invest New Drugs 1 Apr 2008 [Epub ahead of print].
- 06 Nov 2007 Status change from recruiting to in progress